TUTCRIS - Tampereen teknillinen yliopisto

TUTCRIS

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas

Tutkimustuotosvertaisarvioitu

Standard

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. / Granberg, Kirsi J.; Annala, Matti; Lehtinen, Birgitta; Kesseli, Juha; Haapasalo, Joonas; Ruusuvuori, Pekka; Yli-Harja, Olli; Visakorpi, Tapio; Haapasalo, Hannu; Nykter, Matti; Zhang, Wei.

julkaisussa: Neuro-Oncology, Vuosikerta 19, Nro 9, 01.09.2017, s. 1206-1216.

Tutkimustuotosvertaisarvioitu

Harvard

Granberg, KJ, Annala, M, Lehtinen, B, Kesseli, J, Haapasalo, J, Ruusuvuori, P, Yli-Harja, O, Visakorpi, T, Haapasalo, H, Nykter, M & Zhang, W 2017, 'Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas', Neuro-Oncology, Vuosikerta. 19, Nro 9, Sivut 1206-1216. https://doi.org/10.1093/neuonc/nox028

APA

Granberg, K. J., Annala, M., Lehtinen, B., Kesseli, J., Haapasalo, J., Ruusuvuori, P., ... Zhang, W. (2017). Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. Neuro-Oncology, 19(9), 1206-1216. https://doi.org/10.1093/neuonc/nox028

Vancouver

Granberg KJ, Annala M, Lehtinen B, Kesseli J, Haapasalo J, Ruusuvuori P et al. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. Neuro-Oncology. 2017 syys 1;19(9):1206-1216. https://doi.org/10.1093/neuonc/nox028

Author

Granberg, Kirsi J. ; Annala, Matti ; Lehtinen, Birgitta ; Kesseli, Juha ; Haapasalo, Joonas ; Ruusuvuori, Pekka ; Yli-Harja, Olli ; Visakorpi, Tapio ; Haapasalo, Hannu ; Nykter, Matti ; Zhang, Wei. / Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. Julkaisussa: Neuro-Oncology. 2017 ; Vuosikerta 19, Nro 9. Sivut 1206-1216.

Bibtex - Lataa

@article{70eac88e6f3641eaa3e97b008b68f664,
title = "Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas",
abstract = "Background. Inhibitors of fibroblast growth factor receptors (FGFRs) have recently arisen as a promising treatment option for patients with FGFR alterations. Gene fusions involving FGFR3 and transforming acidic coiled-coil protein 3 (TACC3) have been detected in diffuse gliomas and other malignancies, and fusion-positive cases have responded well to FGFR inhibition. As high FGFR3 expression has been detected in fusion-positive tumors, we sought to determine the clinical significance of FGFR3 protein expression level as well as its potential for indicating FGFR3 fusions. Methods. We performed FGFR3 immunohistochemistry on tissue microarrays containing 676 grades II-IV astrocytomas and 116 grades II-III oligodendroglial tumor specimens. Fifty-one cases were further analyzed using targeted sequencing. Results. Moderate to strong FGFR3 staining was detected in gliomas of all grades, was more common in females, and was associated with poor survival in diffuse astrocytomas. Targeted sequencing identified FGFR3-TACC3 fusions and an FGFR3-CAMK2A fusion in 10 of 15 strongly stained cases, whereas no fusions were found in 36 negatively to moderately stained cases. Fusion-positive cases were predominantly female and negative for IDH and EGFR/PDGFRA/MET alterations. These and moderately stained cases show lower MIB-1 proliferation index than negatively to weakly stained cases. Furthermore, stronger FGFR3 expression was commonly observed in malignant tissue regions of lower cellularity in fusion-negative cases. Importantly, subregional negative FGFR3 staining was also observed in a few fusion-positive cases. Conclusions. Strong FGFR3 protein expression is indicative of FGFR3 fusions and may serve as a clinically applicable predictive marker for treatment regimens based on FGFR inhibitors.",
keywords = "Biomarker, Gene fusion, Glioblastoma, Targeted sequencing",
author = "Granberg, {Kirsi J.} and Matti Annala and Birgitta Lehtinen and Juha Kesseli and Joonas Haapasalo and Pekka Ruusuvuori and Olli Yli-Harja and Tapio Visakorpi and Hannu Haapasalo and Matti Nykter and Wei Zhang",
note = "EXT={"}Zhang, Wei{"} EXT={"}Nykter, Matti{"} EXT={"}Kesseli, Juha{"} INT=tut-bmt,{"}Lehtinen, Birgitta{"}",
year = "2017",
month = "9",
day = "1",
doi = "10.1093/neuonc/nox028",
language = "English",
volume = "19",
pages = "1206--1216",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "9",

}

RIS (suitable for import to EndNote) - Lataa

TY - JOUR

T1 - Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas

AU - Granberg, Kirsi J.

AU - Annala, Matti

AU - Lehtinen, Birgitta

AU - Kesseli, Juha

AU - Haapasalo, Joonas

AU - Ruusuvuori, Pekka

AU - Yli-Harja, Olli

AU - Visakorpi, Tapio

AU - Haapasalo, Hannu

AU - Nykter, Matti

AU - Zhang, Wei

N1 - EXT="Zhang, Wei" EXT="Nykter, Matti" EXT="Kesseli, Juha" INT=tut-bmt,"Lehtinen, Birgitta"

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background. Inhibitors of fibroblast growth factor receptors (FGFRs) have recently arisen as a promising treatment option for patients with FGFR alterations. Gene fusions involving FGFR3 and transforming acidic coiled-coil protein 3 (TACC3) have been detected in diffuse gliomas and other malignancies, and fusion-positive cases have responded well to FGFR inhibition. As high FGFR3 expression has been detected in fusion-positive tumors, we sought to determine the clinical significance of FGFR3 protein expression level as well as its potential for indicating FGFR3 fusions. Methods. We performed FGFR3 immunohistochemistry on tissue microarrays containing 676 grades II-IV astrocytomas and 116 grades II-III oligodendroglial tumor specimens. Fifty-one cases were further analyzed using targeted sequencing. Results. Moderate to strong FGFR3 staining was detected in gliomas of all grades, was more common in females, and was associated with poor survival in diffuse astrocytomas. Targeted sequencing identified FGFR3-TACC3 fusions and an FGFR3-CAMK2A fusion in 10 of 15 strongly stained cases, whereas no fusions were found in 36 negatively to moderately stained cases. Fusion-positive cases were predominantly female and negative for IDH and EGFR/PDGFRA/MET alterations. These and moderately stained cases show lower MIB-1 proliferation index than negatively to weakly stained cases. Furthermore, stronger FGFR3 expression was commonly observed in malignant tissue regions of lower cellularity in fusion-negative cases. Importantly, subregional negative FGFR3 staining was also observed in a few fusion-positive cases. Conclusions. Strong FGFR3 protein expression is indicative of FGFR3 fusions and may serve as a clinically applicable predictive marker for treatment regimens based on FGFR inhibitors.

AB - Background. Inhibitors of fibroblast growth factor receptors (FGFRs) have recently arisen as a promising treatment option for patients with FGFR alterations. Gene fusions involving FGFR3 and transforming acidic coiled-coil protein 3 (TACC3) have been detected in diffuse gliomas and other malignancies, and fusion-positive cases have responded well to FGFR inhibition. As high FGFR3 expression has been detected in fusion-positive tumors, we sought to determine the clinical significance of FGFR3 protein expression level as well as its potential for indicating FGFR3 fusions. Methods. We performed FGFR3 immunohistochemistry on tissue microarrays containing 676 grades II-IV astrocytomas and 116 grades II-III oligodendroglial tumor specimens. Fifty-one cases were further analyzed using targeted sequencing. Results. Moderate to strong FGFR3 staining was detected in gliomas of all grades, was more common in females, and was associated with poor survival in diffuse astrocytomas. Targeted sequencing identified FGFR3-TACC3 fusions and an FGFR3-CAMK2A fusion in 10 of 15 strongly stained cases, whereas no fusions were found in 36 negatively to moderately stained cases. Fusion-positive cases were predominantly female and negative for IDH and EGFR/PDGFRA/MET alterations. These and moderately stained cases show lower MIB-1 proliferation index than negatively to weakly stained cases. Furthermore, stronger FGFR3 expression was commonly observed in malignant tissue regions of lower cellularity in fusion-negative cases. Importantly, subregional negative FGFR3 staining was also observed in a few fusion-positive cases. Conclusions. Strong FGFR3 protein expression is indicative of FGFR3 fusions and may serve as a clinically applicable predictive marker for treatment regimens based on FGFR inhibitors.

KW - Biomarker

KW - Gene fusion

KW - Glioblastoma

KW - Targeted sequencing

U2 - 10.1093/neuonc/nox028

DO - 10.1093/neuonc/nox028

M3 - Article

VL - 19

SP - 1206

EP - 1216

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 9

ER -